Drugs / RT-310
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06136819 | Apr 2024 → Dec 2025 overdue | benign prostatic hyperplasia | Resurge Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07264205 | Mar 2025 → Mar 2026 overdue | benign prostatic hyperplasia | Resurge Therapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RT-310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07264205 ↗ |